ASP-440 is a small molecule commercialized by Rezolute, with a leading Phase II program in Diabetic Macular Edema. According to Globaldata, it is involved in 3 clinical trials, of which 2 were completed, and 1 is ongoing. GlobalData uses proprietary data and analytics to provide a complete picture of ASP-440’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
The revenue for ASP-440 is expected to reach an annual total of $65 mn by 2035 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
RZ-402 is under development for the treatment of diabetic macular edema (diabetes-induced retinal vascular permeability). It is administered through oral route. The drug candidate targets plasma kallikrein. It was also under development for treatment of intracerebral hemorrhage (hyperglycemia-induced hematoma expansion) and diabetic retinopathy (DR).
Rezolute formerly, AntriaBio Inc, is a clinical-stage biopharmaceutical company that carries out the development of innovative drug therapies for the treatment of metabolic diseases related to chronic glucose imbalance. Its pipeline product portfolio includes RZ358 which is an intravenous monoclonal antibody. RZ358 is used for the treatment of conditions characterized by excessive insulin levels and is developing to treat hyperinsulinism and low blood sugar characteristic of diseases such as congenital hyperinsulinism. The company also offers RZ402 which is a potent plasma kallikrein inhibitor used for the treatment of diabetic macular edema (DME). Rezolute is headquartered in Redwood City, California, the US.
The operating loss of the company was US$43.4 million in FY2022, compared to an operating loss of US$22.4 million in FY2021. The net loss of the company was US$41.1 million in FY2022, compared to a net loss of US$20.9 million in FY2021.
For a complete picture of ASP-440’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.